Vallon Pharmaceuticals Completes Merger with GRI Bio, Inc.

Combined company will operate as GRI Bio, Inc. and advance innovative pipeline of Natural Killer T (“NKT”) modulating therapies for the treatment of inflammatory, fibrotic and autoimmune diseases

Investment proceeds expected to fund planned operations of the combined company into mid-2024